Boundless Bio Inc. (BOLD)

Boundless Bio, Inc. went public on March 28, 2024, listing on NASDAQ, and its stock has trended up by 24.39% over the past six months. In December 2025, the company participated in the Piper Sandler 37th Annual Healthcare Conference. In January 2026, the FDA accepted the IND application for BBI-940, allowing the initiation of the Phase 1 KOMODO-1 clinical trial in February 2026, accompanied by the discontinuation of the POTENTIATE trial. In February 2026, the company participated in the Guggenheim Emerging Outlook: Biotech Summit 2026. In March 2026, Boundless Bio reported its Fourth Quarter and Full Year 2025 financial results and business highlights and announced an upcoming presentation of its oral Kinesin degrader program at the American Association for Cancer Research Annual Meeting 2026, with an analyst price target increase of 33.33% to $4.08. In April 2026, the company presented preclinical breast cancer data from its oral Kinesin degrader program (BBI-940) at the 2026 AACR Annual Meeting. On May 8, 2026, Boundless Bio reported its First Quarter 2026 financial results and business highlights, showing a narrowed net loss and reduced R&D and G&A expenses, highlighting ongoing enrollment in the KOMODO-1 trial and a cash runway expected to fund operations into the second half of 2028.

The demand for Boundless Bio's products and services is primarily driven by medical need and the progression of its clinical trials, rather than typical seasonal patterns. Demand for cancer treatments is generally constant throughout the year, dictated by disease incidence and patient populations, rather than seasonal fluctuations. Therefore, there is no significant demand seasonality for Boundless Bio's products and services.

Boundless Bio, Inc. is a clinical-stage oncology company focused on developing novel cancer therapeutics by targeting extrachromosomal DNA (ecDNA) biology. Their proprietary Spyglass platform identifies targets essential for ecDNA functionality, enabling the development of ecDNA-directed therapeutic candidates (ecDTx). The company's lead product candidate, BBI-940, is in a Phase 1/2 clinical trial (KOMODO-1) for metastatic breast cancer. BBI-355, an oral, selective inhibitor of checkpoint kinase 1 (CHK1), was being evaluated in the Phase 1/2 POTENTIATE clinical trial, but enrollment has ceased following a strategic portfolio review. BBI-825, an oral, selective inhibitor of ribonucleotide reductase (RNR), was also part of the POTENTIATE trial.

Boundless Bio, Inc. is headquartered in San Diego, California, and is incorporated in Delaware. Its operations and market focus are primarily within the United States.

Boundless Bio's brand reputation is characterized by its pioneering efforts in extrachromosomal DNA (ecDNA) cancer therapeutics, which presents both promise and risks. Potential risks include reliance on a novel and unproven therapeutic approach, discontinuation of clinical trials, and a low GF Score™. Positive developments include FDA acceptance of the IND application for BBI-940, initiation of the KOMODO-1 clinical trial, positive preclinical data for BBI-940, and an extended cash runway into the second half of 2028.

The ownership structure of Boundless Bio Inc. consists of institutional investors (9.41% to 12.26%), insiders (8.19%), and public companies and individual investors (79.55%). Major institutional owners include Fidelity Mt. Vernon Street Trust, Citadel Advisors Llc, Stonepine Capital Management, LLC, Sectoral Asset Management Inc, Vanguard Group Inc, Wellington Management Group Llp, Renaissance Technologies Llc, Alyeska Investment Group, L.P., RBF Capital, LLC, Northern Trust Corp, Arch Venture Partners, L.P., and RA CAPITAL MANAGEMENT, L.P.. Key individual owners and executives include Dr. Jonathan E. Lim and Zachary D. Hornby.